The interleukin-1 (IL-1) family of cytokines has been implicated in the pathogenesis of atherosclerosis in previous studies. The NLRP3 inflammasome has recently emerged as a pivotal regulator of IL-1β maturation and secretion by macrophages. Little is currently known about a possible role for the NLRP3 inflammasome in atherosclerosis progression in vivo. We generated ApoE-/- Nlrp3-/-, ApoE-/- Asc-/- and ApoE-/- caspase-1-/- double-deficient mice, fed them a high-fat diet for 11 weeks and subsequently assessed atherosclerosis progression and plaque phenotype. No differences in atherosclerosis progression, infiltration of plaques by macrophages, nor plaque stability and phenotype across the genotypes studied were found. Our results demonstrat...
Apolipoprotein E3-Leiden (APOE3-Leiden) transgenic mice develop hyperlipidemia and are highly suscep...
Despite decades of research, our understanding of the processes controlling late-stage atherosclerot...
Background: The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that ant...
Background: The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β...
Objective: To examine the role of the balance between interleukin (IL)-1 and IL-1 receptor antagonis...
Background: The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β...
Although Nlrp3 inflammasome activation in macrophages has been shown to be critical for the developm...
Objectives. The role of the NLRP3 inflammasome in atherosclerosis remains controversial. The aim of ...
The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflamma...
Activation of macrophage inflammasomes leads to interleukin (IL)-1b and IL-18 secretion and promotes...
PLEASE NOTE: This work is protected by copyright. Downloading is restricted to the BU community: ple...
Background: Atherosclerosis is an inflammatory process that develops in individuals with known risk ...
Item does not contain fulltextOBJECTIVE: Interleukin (IL)-1alpha and IL-1beta are products of macrop...
Background: The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that ant...
Background The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β ...
Apolipoprotein E3-Leiden (APOE3-Leiden) transgenic mice develop hyperlipidemia and are highly suscep...
Despite decades of research, our understanding of the processes controlling late-stage atherosclerot...
Background: The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that ant...
Background: The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β...
Objective: To examine the role of the balance between interleukin (IL)-1 and IL-1 receptor antagonis...
Background: The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β...
Although Nlrp3 inflammasome activation in macrophages has been shown to be critical for the developm...
Objectives. The role of the NLRP3 inflammasome in atherosclerosis remains controversial. The aim of ...
The inflammatory nature of atherosclerosis is well established but the agent(s) that incite inflamma...
Activation of macrophage inflammasomes leads to interleukin (IL)-1b and IL-18 secretion and promotes...
PLEASE NOTE: This work is protected by copyright. Downloading is restricted to the BU community: ple...
Background: Atherosclerosis is an inflammatory process that develops in individuals with known risk ...
Item does not contain fulltextOBJECTIVE: Interleukin (IL)-1alpha and IL-1beta are products of macrop...
Background: The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that ant...
Background The NLR family, pyrin domain containing 3 (NLRP3) inflammasome is an interleukin (IL)‐1β ...
Apolipoprotein E3-Leiden (APOE3-Leiden) transgenic mice develop hyperlipidemia and are highly suscep...
Despite decades of research, our understanding of the processes controlling late-stage atherosclerot...
Background: The CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) showed that ant...